Everything below concerns retatrutide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 4,700 Da | Peptide of roughly forty amino acids |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist class |
| Research code | LY3437943 | Internal development designation |
| Compound class | Incretin mimetic peptide | Synthetic, not a biologic extract |
| Development status | Investigational | No general regulatory approval |
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
== Human homologue == Agouti signaling protein (ASP) is the human homologue of murine agouti. It is encoded by the human agouti gene on chromosome 20 and is a protein consisting of 132 amino acids. It is expressed much more broadly than murine agouti and is found in adipose tissue, pancreas, testes, and ovaries, whereas murine agouti is solely expressed in melanocytes. ASP has 85% similarity to the murine form of agouti. As ectopic expression of murine agouti leads to the development of the yellow obese syndrome, this is expected to be consistent in humans. The yellow obese syndrome increases the development of many chronic diseases, including obesity, type II diabetes mellitus and tumorigenesis. ASP has similar pharmacological activation to murine agouti, as melanocortin receptors are inhibited through competitive antagonism. Inhibition of melanocortin by ASP can also be through non-competitive methods, broadening its range of effects. The function of ASP differs to murine agouti. ASP effects the quality of hair pigmentation whereas murine agouti controls the distribution of pigments that determine coat color. ASP has neuroendocrine functions consistent with murine agouti, as it agonizes via AgRP neurons in the hypothalamus and antagonizes MSH at MC4Rs which reduce satiety signals. AgRP acts as an appetite stimulator and increases appetite while decreasing metabolism. Because of these mechanisms, AgRP may be linked to increased body mass and obesity in both humans and mice.
Mepsy (formerly Policy Analysis Modeling System (PAMS)) Based on the Policy Analysis Modeling System created by CLASP and the Lawrence Berkeley National Laboratory (LBNL), Mepsy is as an easy-to-use software tool to help local policymakers assess the benefit of standards and labeling programs, and to identify the most attractive targets for appliances and efficiency levels. CLASP Policy Resource Center (CPRC) (formerly Global S&L Database) The CLASP Policy Resource Center is an online resource that allows policy makers and S&L practitioners to compare appliance, lighting, and equipment efficiency policies and regulations across countries and by product; to explore specific information about those policies; and to view and understand the legislative framework and history of S&L by country and economic region. VeraSol (formerly Lighting Global Quality Assurance) VeraSol evolved from Lighting Global Quality Assurance, a quality assurance initiative for off-grid solar products supported by the World Bank. Products in the database display technical information that can be compared across appliance categories and have been undergone testing in certified laboratories.
Main course (often referred to as "the main") Side dish Dessert or snack (often commercial candy, fortified pastry, First Strike Bar, or Soldier Fuel) Crackers or bread Cheese spread, peanut butter, or jelly Powdered beverage mix (commonly a fruit-flavored drink, cocoa, protein drink powder, instant coffee or tea, sport drink, or dairy shake) Utensils (commonly just a plastic spoon, though rarely a fork and knife may also be given) Flameless ration heater Beverage mixing bag Accessory pack: Xylitol chewing gum Water-resistant matchbook Napkin / toilet paper Moist towelette Seasonings, including salt, pepper, sugar, creamer, and/or Tabasco sauce Freeze-dried coffee powder Many items are fortified with nutrients. In addition, DoD policy requires units to augment MREs with fresh food whenever feasible, especially in training environments.
a bolus dose that is pumped to cover food eaten or to correct a high blood glucose level. a basal dose that is pumped continuously at an adjustable basal rate to deliver insulin needed between meals and at night.
==== Motivation ==== Testosterone levels play a major role in risk-taking during financial decisions. Higher testosterone levels in men reduce the risk of becoming or staying unemployed. Research has also found that heightened levels of testosterone and cortisol are associated with an increased risk of impulsive and violent criminal behavior. On the other hand, elevated testosterone in men may increase their generosity, primarily to attract a potential mate.
Sources: en.wikipedia.org
The People's Pharmacy received multiple reports of increased side effects and decreased efficacy of generic bupropion, which prompted it to ask ConsumerLab.com to test the products in question. The tests showed that "one of a few generic versions of Wellbutrin XL 300 mg, sold as Budeprion XL 300 mg, didn't perform the same as the brand-name pill in the lab." The FDA investigated these complaints and concluded that Budeprion XL is equivalent to Wellbutrin XL regarding bioavailability of bupropion and its main active metabolite hydroxybupropion. The FDA also said that coincidental natural mood variation is the most likely explanation for the apparent worsening of depression after the switch from Wellbutrin XL to Budeprion XL. On 3 October 2012, however, the FDA reversed this opinion, announcing that "Budeprion XL 300 mg fails to demonstrate therapeutic equivalence to Wellbutrin XL 300 mg." The FDA did not test the bioequivalence of any of the other generic versions of Wellbutrin XL 300 mg, but requested that the four manufacturers submit data on this question to the FDA by March 2013. As of October 2013 the FDA has made determinations on the formulations from some manufacturers not being bioequivalent. In April 2008, the FDA approved a formulation of bupropion as a hydrobromide salt instead of a hydrochloride salt, to be sold under the name Aplenzin by Sanofi-Aventis. It is an extended-release tablet intended for once-daily use. It was approved on the basis of bioequivalence with Wellbutrin XL.
=== Flavin-dependent ene-reductases === Flavin-dependent ERs perform their reactions using the cofactor flavin mononucleotide (FMN) that is non-covalently bonded to the enzyme and their catalytic mechanism is now well understood. In the natural cycle, the cofactor (FMN) is first reduced by NAD(P)H, then the reduced FMNH2 reduces the substrate by Michael-type hydride transfer to the β-carbon atom. In the end the protonation of the resulting anion occurs from the opposite face of the (C=C) bond through a tyrosine moiety or solvent. The overall reaction is an anti-trans-hydrogenation. This catalytic mechanism can also be regenerated from the natural nicotinamide cofactor with a substrate-coupled regeneration or the use of synthetic reductants and electrochemical or photochemical regeneration. The most predominant family of flavin-dependent ERs is the Old Yellow Enzyme (OYE) family of oxidoreductases (EC 1.6.99.1).The first OYE was discovered in baker's yeast (Saccharomyces cerevisiae) in 1933, and its name derives from the color it assumes when concentrated, which is due to the flavin cofactor. They catalyze the reduction of α,β-unsaturated compounds, with a high specificity for activating groups containing aldehydes, ketones, or nitro groups. Conversely, carboxylic acids and their derivatives such as esters and nitriles, are less activated and are considered as "borderline substrates".
== Further reading == Almond, Mark (2002). Uprising!: Ideological Shifts and Political Upheavals That Have Shaped the World. London: Octopus Publishing Group. ISBN 978-0-7607-3348-6. Garton Ash, Timothy (1990). The magic lantern: the revolution of '89 witnessed in Warsaw, Budapest, Berlin, and Prague. New York: Random House. ISBN 978-0-394-58884-1. Deletant, Dennis (1999). Romania under communist rule. Iasi: The Center for Romanian Studies. ISBN 978-973-98392-8-0. Gives a detailed account of the events in December 1989 in Timișoara. Engel, Jeffrey A. (2017). When the world seemed new: George H.W. Bush and the end of the Cold War. Boston; New York: Houghton Mifflin Harcourt. ISBN 978-0-547-42306-7. Ștefănescu, Domnița (1995). Cinci ani din istoria Romaniei: o cronologie a evenimentelor (decembrie 1989-decembrie 1994) [Five years of Romanian history: a chronology of events (December 1989-December 1994)] (in Romanian). Bucharest: Mașina de Scris. ISBN 978-9-73-971622-2. OCLC 909545436.
The newer restaurant concepts did not perform as well as they had hoped, so ShopHouse Southeast Asian Kitchen and Tasty Made were closed in March 2017 and February 2018 respectively, leaving only Pizzeria Locale operating besides the parent company. In February 2023, Chipotle opened their first Farmesa Fresh Eatery in Santa Monica, California, serving bowls containing customers' choice of a protein, a green or grain, two sides, a topping, and a selection of up to five sauces. Some of the choices included steak, salmon, whipped potatoes, sweet potato chips, beets, and cauliflower. In July 2023, Chipotle exited the highly competitive pizza restaurant industry by announcing that they were closing all of their remaining Pizzeria Locale locations and would "dissolve the business". Chipotle also abandoned Farmesa in April 2024.
Sources: en.wikipedia.org
Arenobufagin is believed to play a role in the regulation of the transport of water and electrolytes across cell membranes under physiological conditions. Experimental results show that Arenobufagin inhibits the sodium-potassium adenosine triphosphatase (Na+/K+-ATPase) . It is one of the most potent blockers that are known to science, along with ouabain. It has been suggested that uncharged and non-polar amino acids may participate in the binding of arenobufagin to the extracellular surface of the ATPase. If this is the case, the steroid nucleus of arenobufagin probably also contributes to the binding. Furthermore, the presence of a sugar group in ouabain and the absence of one in arenobufagin suggests that it may me more lipophilic that ouabain and as such form a more stable complex with the Na+-K+ pump. Besides its effects on the Na+-K+ pump, arenobufagin also has some other effects on cells, which were discovered in experiment with cancer cell lines. It causes apoptosis by tempering with mitochondria. In cells treated with it, a decreasing mitochondrial potential was detected (in a dose-dependent manner), as well as a high Bax/Bcl-2 ratio, which is associated with apoptosis, or programmed cell death. Bax translocation from cytosol to mitochondria was also found to be increased. In addition to these effects, arenobufagin also induces morphological changes in organelles, blebbing of plasma membrane, shrinkage of nuclear membrane and chromatin condensation. These observation also indicate the occurrence of apoptosis.
Because β-alanine dipeptides are not incorporated into proteins, they can be stored at relatively high concentrations. Occurring at 17–25 mmol/kg (dry muscle), carnosine (β-alanyl-L-histidine) is an important intramuscular buffer, constituting 10-20% of the total buffering capacity in type I and II muscle fibres. In carnosine, the pKa of the imidazolium group is 6.83, which is ideal for buffering.
That month, Amnesty International published their report, finding that Gaddafi's forces were responsible for numerous war crimes but added that a number of allegations of human rights abuses lacked credible evidence. The report added that "much Western media coverage has from the outset presented a very one-sided view of the logic of events, portraying the protest movement as entirely peaceful and repeatedly suggesting that the regime's security forces were unaccountably massacring unarmed demonstrators". In July, over 30 governments recognized the NTC as the legitimate government of Libya; Gaddafi called on his supporters to "Trample on those recognitions, trample on them under your feet ... They are worthless". In August, the Arab League recognized the NTC as "the legitimate representative of the Libyan state". Aided by NATO air cover, the rebel militia pushed westward, defeating loyalist armies and securing control of the centre of the country. Gaining the support of Amazigh (Berber) communities of the Nafusa Mountains, who had long been persecuted as non-Arabic speakers under Gaddafi, the NTC armies surrounded Gaddafi loyalists in several key areas of western Libya. In August, the rebels seized Zliten and Tripoli, ending the last vestiges of Gaddafist power. It is probable that without the NATO air strikes supporting the rebels, they would not have been able to advance west and Gaddafi's forces would have ultimately retaken control of eastern Libya.
Sources: en.wikipedia.org
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.
No regulatory agency has approved it for routine medical use. It remains an investigational compound studied in controlled trials. Access outside research settings is not established.
Each receptor influences energy balance through different pathways. Combining them is intended to add fat loss from lowered intake and higher expenditure. The optimal balance among the three effects is still under study.
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.